Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Endeavour Silver to Rejig Guidance After Disruptions, Despite Rise in 3Q Output

Endeavour Silver to Rejig Guidance After Disruptions, Despite Rise in 3Q Output

Dow JonesDow Jones2026/10/08 12:03

By Robb M. Stewart Endeavour Silver plans to revise its production targets for the year after disruptions held back growth in the latest quarter. The Canadian silver producer with mines in Mexico and Peru said annual production is expected to be at or slightly below the low end of its latest guidance following operational interruptions at the Terronera and Guanacevi operations. Endeavour early this year forecast silver-equivalent production of between 14.6 million and 15.6 million ounces in 2026, including 8.3 million to 8.9 million ounces of silver and 46,000 to 48,000 ounces of gold from its Terronera, Guanacevi and Kolpa mines. Output in the third quarter totaled 3.61 million silver-equivalent ounces, up 19% on a year earlier. For the first nine months of the year, production was 40% higher at 10.39 million ounces. Chief Executive Dan Dickson said that despite temporary disruptions, the Terronera plant reached optimal processing performance and the Kolpa expansion exceeded expectations. Operations at the Terronera mine were suspended for about 12 days in August due to a blockade, while the mill at Guanacevi was taken offline in September to replace parts and conduct repairs that are expected to be completed in the first half of October. Write to Robb M. Stewart at robb.stewart@wsj.com (END) Dow Jones Newswires October 08, 2026 08:03 ET (12:03 GMT)

By Robb M. Stewart

Endeavour Silver plans to revise its production targets for the year after disruptions held back growth in the latest quarter.

The Canadian silver producer with mines in Mexico and Peru said annual production is expected to be at or slightly below the low end of its latest guidance following operational interruptions at the Terronera and Guanacevi operations.

Endeavour early this year forecast silver-equivalent production of between 14.6 million and 15.6 million ounces in 2026, including 8.3 million to 8.9 million ounces of silver and 46,000 to 48,000 ounces of gold from its Terronera, Guanacevi and Kolpa mines.

Output in the third quarter totaled 3.61 million silver-equivalent ounces, up 19% on a year earlier. For the first nine months of the year, production was 40% higher at 10.39 million ounces.

Chief Executive Dan Dickson said that despite temporary disruptions, the Terronera plant reached optimal processing performance and the Kolpa expansion exceeded expectations. Operations at the Terronera mine were suspended for about 12 days in August due to a blockade, while the mill at Guanacevi was taken offline in September to replace parts and conduct repairs that are expected to be completed in the first half of October.

Write to Robb M. Stewart at robb.stewart@wsj.com

(END) Dow Jones Newswires

October 08, 2026 08:03 ET (12:03 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss